Literature DB >> 1324649

Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

D Shonekan1, D Mildvan, S Handwerger.   

Abstract

The in vitro activities of teicoplanin, daptomycin, ramoplanin, and PD127,391, a new quinolone, were compared with that of vancomycin. Teicoplanin showed the lowest MICs against Enterococcus faecalis. Ramoplanin was slightly more active than the other peptide antibiotics against oxacillin-resistant Staphylococcus aureus. The MICs of the four peptide antibiotics were similar for the oxacillin-susceptible S. aureus. Daptomycin had good activity against staphylococci but was the least active agent against E. faecalis. The MICs of vancomycin against all isolates were in general higher than those of the new antibiotics, with the exceptions of the MICs of daptomycin against E. faecalis and teicoplanin against oxacillin-resistant Staphylococcus epidermidis. PD127,391 was the most active agent against all staphylococcal isolates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324649      PMCID: PMC191623          DOI: 10.1128/AAC.36.7.1570

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Antibacterial activities and modes of action of vancomycin and related glycopeptides.

Authors:  R Nagarajan
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  Clinical efficacy and safety of teicoplanin.

Authors:  W Stille; W Sietzen; H A Dieterich; J J Fell
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

4.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

5.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

6.  Inhibition of membrane potential-dependent amino acid transport by daptomycin.

Authors:  N E Allen; W E Alborn; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

7.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecium 228.

Authors:  S Handwerger; M J Pucci; A Kolokathis
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.

Authors:  D M Shlaes; A Bouvet; C Devine; J H Shlaes; S al-Obeid; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

10.  Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  11 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration.

Authors:  M J Michiels; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 7.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

Review 8.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.

Authors:  S Burney; D Landman; J M Quale
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.